No Data
No Data
Nomura Adjusts WuXi XDC Cayman's Price Target to HK$28.91 From HK$32.52, Keeps at Buy
WuXi XDC Issues Restricted Shares to Staff
WuXi AppTec (02268.HK) has been approved to grant 4.4969 million restricted shares to 211 grantees.
On July 12th, GLH (02268.HK) announced that under the 2024 stock plan, it had approved the grant of 4,496,948 restricted shares to 211 grantees on July 12th, 2024. Three of the grantees are directors, while the remaining 208 are group employees and must be accepted by selected participants.
Hong Kong stock market anomaly|Yao Ming He Lian (02268) rose more than 5%: ADC drug research and development and active external authorization trading, the company's commercialization is promising.
Zhītōng Finance app learned that Jiangsu Hengrui Medicine (02269) is now up more than 5%, as of the time of publication, up 4.22%, at HKD 15.8, and trading at HKD 17.5152 million. Swhy points out that due to the more precise targeting of ADC drugs compared to traditional small molecules, as well as a wider therapeutic window compared to monoclonal antibody drugs, the ADC drug market is expected to achieve rapid growth; Since the technical path of ADC drugs is clear and commercialization certainty is higher, the number of global ADC drug licensing transactions has grown rapidly since 2022, and the total transaction amount has also significantly increased. The bank pointed out that this was achieved through 'empowerment, follow-up'.
Are Investors Undervaluing WuXi XDC Cayman Inc. (HKG:2268) By 39%?
[Brokerage Focus] Bocom Intl expects current high cost performance in medical sector, but industry sentiment has not fully recovered.
Jingu Finance Xintong | Bank of Communications International released the outlook for the pharmaceutical industry in the second half of 2024. They think that the pharmaceutical sector currently has high cost-effectiveness, but institutional positions have fallen to a low level and industry sentiment has not fully recovered. The bank recommends laying out three main themes in 2H24: 1) The Davis double-click opportunity of valuation bottoming out and performance rebounding; 2) Innovation is the theme of the industry's long-term development, taking into account the potential for product export; 3) Defensive opportunities with stable performance and high shareholder returns. The bank's preference ranking for segmented sectors is as follows: prescription drugs = innovative drugs > high dividend traditional Chinese medicine/circulation > private hospitals > CXO. Specifically, prescription drugs - performance growth rebound + valuation.
No Data